Skip to main content

Table 3 Patient characteristics characterized according to whether the patients received tamoxifen (TAM) or toremifene (TOR) treatment

From: A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study

 

TAM (n = 240)

TOR (n = 212)

P value

Age

  

0.552

18-34

34

26

 

>35

206

186

 

T

  

0.744

 1

147

137

 

 2

84

67

 

 3

9

8

 

N

  

0.536

 0

142

136

 

 1-3

61

52

 

 4-9

27

19

 

 ≥10

10

5

 

AJCC Stage

  

0.616

 I

98

97

 

 IIA

70

64

 

 IIB

32

25

 

 IIIA

30

21

 

 IIIB

0

0

 

 IIIC

10

5

 

HER-2 status

  

0.359

 Positive

37

23

 

 Negative

148

137

 

 Unknown

55

52

 

Grade

  

0.328

 I

51

37

 

 II

141

120

 

 III

47

52

0.530

 Unknown

1

3

 

Risk of recurrence

  

0.313

 Low

11

15

 

 Intermediate or

229

197

 

 high

  

0.024

Local control

117

130

 

 BCS + RT

90

57

 

 Modified

33

25

 

 Modified + RT

  

0.513

Chemotherapy

15

10

 

 CMF

96

92

 

 ET

62

42

 

 FEC

43

45

 

 TC

24

23

 

 No chemotherapy

   
  1. Differences between the two groups were evaluated using a χ2 test.
Back to article page